Subscribe To
PRQR / Why ProQR Therapeutics Stock Got Slammed Again Monday
PRQR News
By Seeking Alpha
July 9, 2023
ProQR: Too Many Failures For Its RNA Technology
PRQR, last year, failed a pivotal trial. This is the third time it has failed trials after showing early signs of efficacy. While they are making an e more_horizontal
By Zacks Investment Research
May 16, 2023
ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates
ProQR (PRQR) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.22 per share a y more_horizontal
By The Motley Fool
March 29, 2023
Why Shares of ProQR Therapeutics Dropped on Wednesday
ProQR focuses on RNA cell-editing therapies to treat rare diseases. The company lost roughly $117 million in cash in 2022. more_horizontal
By Zacks Investment Research
December 23, 2022
ProQR (PRQR) Rises on Expanding RNA-Editing Deal With Eli Lilly
ProQR (PRQR) expands its existing licensing and collaboration agreement with Eli Lilly for the discovery, development and commercialization of new gen more_horizontal
By InvestorPlace
December 22, 2022
Why Is ProQR (PRQR) Stock Up 83% Today?
ProQR (NASDAQ: PRQR ) stock is rising on Thursday thanks to an expanded licensing and collaboration agreement with Eli Lilly (NYSE: LLY ). This agreem more_horizontal
By Schaeffers Research
December 22, 2022
2 Biotech Stocks Making Headlines
Two biotech stocks are in the spotlight today, ProQR Therapeutics NV (NASDAQ:PRQR) and Mirati Therapeutics Inc (NASDAQ:MRTX), with the former attrac more_horizontal
By GlobeNewsWire
December 22, 2022
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to chang more_horizontal
By GlobeNewsWire
November 14, 2022
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedica more_horizontal